Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
TERMEER HENRI A
   2. Issuer Name and Ticker or Trading Symbol
ABIOMED INC [ABMD] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O ABIOMED, INC., 22 CHERRY HILL DRIVE		 3. Date of Earliest Transaction (Month/Day/Year)
02/22/2011
(Street)

DANVERS, MA 01923		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 par value               60,100 D  
Common Stock, $0.01 par value 02/22/2011   S   200 D $ 13.02 (6) 1,827,380 I by Genzyme Corporation (3)
Common Stock, $0.01 per value 02/22/2011   S   8,018 D $ 12.8919 (7) 1,819,362 I by Genzyme Corporation (3)
Common Stock, $0.01 par value 02/23/2011   S   3,436 D $ 12.7843 (8) 1,815,296 I by Genzyme Corporation (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (1) $ 19.69             08/09/2001(2) 08/09/2010 Common Stock 5,000   5,000 D  
Stock Option (right to buy) (1) $ 18.4             08/08/2002(2) 08/08/2012 Common Stock 5,000   5,000 D  
Stock Option (right to buy) (1) $ 4.71             08/06/2003(2) 08/06/2013 Common Stock 5,000   5,000 D  
Stock Option (right to buy) (1) $ 5.15             08/13/2004(2) 08/13/2014 Common Stock 5,000   5,000 D  
Stock Option (right to buy) (4) $ 10.41             08/11/2005(2) 08/11/2014 Common Stock 8,000   8,000 D  
Stock Option (right to buy) (4) $ 10.06             08/09/2006(2) 08/10/2015 Common Stock 8,000   8,000 D  
Stock Option (right to buy) (4) $ 13.21             08/08/2007(2) 08/09/2016 Common Stock 8,000   8,000 D  
Stock option (right to buy) (4) $ 12.69             08/13/2008(2) 08/08/2017 Common Stock 8,000   8,000 D  
Stock Option (right to buy) (5) $ 18.63             08/12/2009(2) 08/13/2018 Common Stock 8,000   8,000 D  
Stock Option (right to buy) (5) $ 7.67             08/11/2010(2) 08/12/2019 Common Stock 12,000   12,000 D  
Stock Options (right to buy) (5) $ 9.99             08/10/2011 08/11/2020 Common Stock 12,000   12,000 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
TERMEER HENRI A
C/O ABIOMED, INC.
22 CHERRY HILL DRIVE
DANVERS, MA 01923		   X      

Signatures

 /s/ Ian W. McLeod (by power of attorney)   02/24/2011
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 1989 Non-Qualified Stock Option Plan for Non-Employee Directors.
(2) This option becomes exercisable in full on the date set forth in Table II, Column 6.
(3) The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for the purposes of Section 16 or for any other purposes. The reporting person is the Chief Executive Officer of Genzyme Corporation.
(4) Grant to reporting person of option to buy the number of shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2000 Stock Incentive Plan.
(5) Grant to reporting person of option to buy shares of Common Stock set forth in Table II, Column 7, under the ABIOMED, Inc. 2008 Stock Incentive Plan.
(6) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $12.85 and $13.02. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
(7) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $12.85 and $12.93. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.
(8) This price represents the weighted average sale price of multiple transactions on the reported date at prices that ranged between $12.75and $12.845. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer, or a security holder of the Issuer.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.